adebrelimab + dalpiciclib + goserelin + letrozole

This entry describes a combination therapy consisting of adebrelimab, dalpiciclib, goserelin, and letrozole. However, the provided search results primarily detail the combination of goserelin and letrozole. Goserelin and letrozole are commonly used together as a hormone therapy for hormone receptor-positive breast cancer, especially in premenopausal women. Goserelin, a luteinizing hormone-releasing hormone (LHRH) analog, suppresses ovarian function (creating a temporary menopause), while letrozole, an aromatase inhibitor, reduces estrogen production in the body. This combined action effectively lowers estrogen levels. The combination of goserelin and letrozole has shown clinical efficacy in premenopausal women with advanced breast cancer, with reported objective response rates of 21.1% to 25.7% and median progression-free survival of 9.5 to 10 months. It is administered as goserelin 3.6 mg subcutaneously every 4 weeks and letrozole 2.5 mg daily by mouth, with goserelin typically started 6 to 8 weeks before letrozole. Treatment duration varies from 5-10 years for primary breast cancer to ongoing for metastatic disease. A notable side effect is bone mineral density loss. The search results do not provide specific information about adebrelimab (an anti-PD-L1 antibody) or dalpiciclib (a CDK4/6 inhibitor) in this particular four-drug combination, although CDK4/6 inhibitors are sometimes used with letrozole in other breast cancer regimens.